The success rate of small renal mass core needle biopsy and its impact on lowering benign resection rate

Background Small renal mass (SRM) biopsy remains under-utilized due to stigma.

Meanwhile, the alarmingly high benign findings in resected kidney masses highlight the need for improved preoperative diagnosis and patient selection.

Methods The purpose of this study is to review the success rate of SRM biopsy and to evaluate its impact on patient management.

A total of 168 percutaneous image-guided core needle biopsies (CNBs) of SRMs were retrieved at a tertiary academic center between 2015 and 2019.

Subsequent treatment choices, side effects and outcomes were retrospectively reviewed.

Results The diagnostic rate of CNB was 86.9%.

Benign neoplasms accounted for a significant portion (14.3%) of SRM.

Renal cell carcinomas (RCCs) were the most common diagnoses (69.6%) as expected.

In biopsy-resection correlation, the positive predictive value of CNB was 100%.

Tumor typing and subtyping by CNB were highly accurate, 100% and 98.3% respectively.

Nuclear grading for clear cell RCC was accurate in 83.8% cases.

The CNB results had significant impact on treatment.

Most patients with RCCs underwent either resection (54.1%) or ablation (33.9%), in contrast to observation in benign neoplasms (90.5%).

Most importantly, the benign resection rate (3.2%) in this series was much lower than the national average.

Conclusion CNB provided accurate diagnoses for the majority of SRMs and revealed benign diagnoses in a subset of clinically suspicious lesions.

Employment of CNB in suspicious SRM may help avoid overtreatment for benign lesions.